Literature DB >> 2182580

The role of the H-ras oncogene in radiation resistance and metastasis.

W G McKenna1, M C Weiss, V J Bakanauskas, H Sandler, M L Kelsten, J Biaglow, S W Tuttle, B Endlich, C C Ling, R J Muschel.   

Abstract

The sensitivity of tumor cells to the killing effects of ionizing radiation is thought to be one of the major determinants of curability of tumors in patients treated with radiation therapy. This paper reviews the evidence from our laboratory and other groups which supports a role for oncogenes in the induction of radioresistance in cultured mammalian cells. Primary rat embryo cells (REC) were chosen as a model system in which the effects on radiation resistance of the H-ras oncogene could be studied on a uniform genetic background. These cells offered several useful advantages. The cells prior to transformation are diploid and because they have been in culture only for a few passages prior to transformation with the oncogene it is unlikely that any preexisting mutation affecting radiation response could be present. Additionally, the use of REC permitted the study of the effects of synergism between oncogenes on the induction of the radioresistant phenotype. The results show that the activated H-ras oncogene induces radiation resistance in primary rat cells after transformation, but that the effect of the oncogene itself is small. However, the myc oncogene, which has no effect on radiation resistance by itself, appears to have a synergistic effect on the induction of radiation resistance by H-ras. Radiation resistance induced by H-ras plus myc is characterized by an increase in the slope of the curve at high doses but there is also a large effect within the shoulder region of the radiation survival curve. The AdenoE1A oncogene which will also act synergistically with ras in transformation assays plays a less clear-cut role in assays of radiation resistance. The H-ras oncogene is also known not only to transform cells but also to induce metastatic behavior in the tumors which form after these transformed cells are injected into syngeneic animals or nude mice. We have also shown in our primary rat embryo cell system that the induction of metastatic behavior in transformed cells, like the induction of radioresistance depends on a complex interaction between oncogenes and the cellular background. This evidence will be reviewed to demonstrate some of the analogies between radiation resistance and metastasis as examples of the complex alterations in cellular phenotype which occur after oncogene transfection.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2182580     DOI: 10.1016/0360-3016(90)90407-b

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

1.  Role of transfection and clonal selection in mediating radioresistance.

Authors:  F S Pardo; R G Bristow; A Taghian; A Ong; C Borek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

3.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 4.  The biology of radioresistance: similarities, differences and interactions with drug resistance.

Authors:  S N Powell; E H Abraham
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 5.  Molecular radiobiology: the state of the art.

Authors:  Amato J Giaccia
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

6.  Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.

Authors:  Deviney Chaponis; Jessica W Barnes; Jamie L Dellagatta; Santosh Kesari; Eva Fast; Claire Sauvageot; Dipak Panagrahy; Emily R Greene; Naren Ramakrishna; Patrick Y Wen; Andrew L Kung; Charles Stiles; Mark W Kieran
Journal:  J Neurooncol       Date:  2011-01-19       Impact factor: 4.130

7.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.

Authors:  Robert Lustig; Tom Mikkelsen; Glenn Lesser; Stuart Grossman; Xiaobu Ye; Serena Desideri; Joy Fisher; John Wright
Journal:  Neuro Oncol       Date:  2008-08-25       Impact factor: 12.300

Review 9.  Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer.

Authors:  N Kyprianou
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

10.  Impact of accumulated alterations in driver and passenger genes on response to radiation therapy.

Authors:  Yuji Seo; Keisuke Tamari; Yutaka Takahashi; Kazumasa Minami; Fumiaki Isohashi; Osamu Suzuki; Iori Sumida; Kazuhiko Ogawa
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.